INTRODUCTION
Mental illness affects one in four Americans 1 and is associated with worse health outcomes. Among patients with various medical illnesses, those with mental health conditions (MHCs) encounter greater barriers to care, receive less intense management, undergo fewer interventions, and experience worse outcomes. [2] [3] [4] [5] [6] [7] Factors contributing to some of these observations include non-adherence, fragmentation of care, stigma, and biases. [8] [9] [10] Warfarin is a widely used anticoagulant, but its utility can only be optimized with regular evaluation and dose adjustment, which promote improved anticoagulation control. 11 Percent time in the therapeutic range (TTR) provides a summary measure of overall anticoagulation control, with lower TTR being associated with more adverse outcomes, such as stroke, venous thromboembolism, and major hemorrhage. [11] [12] [13] [14] [15] Among patients with atrial fibrillation, those with MHCs are known to be less likely to be started on warfarin therapy, 16 and are more likely to have poorly controlled therapy 17 and to experience adverse events such as hemorrhage and stroke. 18 However, important questions regarding MHC and warfarin therapy remain unanswered. We do not know which MHCs are most strongly associated with low TTR and adverse events, and whether MHC-specific risk factors, Electronic supplementary material The online version of this article (doi:10.1007/s11606-014-2784-2) contains supplementary material, which is available to authorized users.
such as a history of psychiatric hospitalization or the Global Assessment of Functioning (GAF) score, can help to identify an especially vulnerable subgroup of patients.
We sought to examine the association of specific MHCs with anticoagulation control and major hemorrhage; to determine the portion of risk for hemorrhage attributable to poor anticoagulation control; and to examine the ability of additional MHC-specific severity indicators-GAF and psychiatric hospitalization-to more precisely determine risk for patients with MHCs receiving warfarin therapy. We hypothesized that different MHCs would affect anticoagulation control and bleeding non-uniformly and that psychiatric diagnoses, GAF scores, and psychiatric hospitalization history would be independent predictors of lower TTR and increased incidence of major hemorrhage.
METHODS

Study Population
We used data from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA), 17, 19 which included patients receiving warfarin therapy from the Veterans Health Administration (VHA) between October 1, 2006 and September 30, 2008 . To eliminate the complexities uniquely associated with therapy initiation, we only included data from the 103,897 "experienced" warfarin users, who had been on warfarin for at least 6 months (Table 1) . We excluded patients with valvular heart disease or mechanical heart valves because of their different INR goals. The study was approved by the Institutional Review Board of the Bedford Veterans Affairs (VA) Medical Center.
Categories of Mental Health Disorders
We identified six categories of MHC: anxiety disorders, bipolar disorder, major depressive disorder, post-traumatic stress disorder (PTSD), schizophrenia, and other psychotic disorders. Online Appendix 1 lists the International Classification of Disease, 9th Revision (ICD-9) codes that comprise each category. We also compared the proportions of patients with MHCs in our cohort to historical norms based on the 1999 Veterans' Large Health Survey 20 (Online Appendix 5).
Independent Variable: GAF Score
GAF is a component of comprehensive psychiatric assessment and is scored on a scale of 0 to 100 based on a patient's overall psychological, occupational, and social function and symptom severity. 21 A lower score suggests worse function or symptoms. A directive from the VHA in 1999 recommended that mental health patients be rated a GAF at time of discharge from psychiatric hospitalization and at least once every 90 days during active outpatient treatment. 22 While some studies have found an association between GAF and patient outcomes, 22, 23 other studies have casted doubt on the utility of the GAF score for predicting clinical outcomes and allocating resources. 24, 25 Because GAF is scored based on the lowest level of function or worst symptom, typically over the previous week 21, 26, 27 , we examined all GAF scores for patients with MHCs and selected the lowest GAF during the 2-year study period. Analysis using mean GAF scores had similar results (Online Appendix 3, Table 5 ). We also partitioned GAF into four groups based on severity descriptors 21 . GAF scores of 0-30, 31-50, 51-70, and 71-100 correspond to severe impairment with hallucination and suicidal symptoms, major impairments and serious symptoms, mild to moderate symptoms, and transient or no impairment or symptoms, respectively. p<0.001 for all comparisons (t-test and chi-square) *Patients with valvular heart disease or mechanical heart valves were excluded
We assigned the 12,471 patients without documented GAF a "missing GAF" indicator and contrasted the characteristics of these patients with those with GAF (Online Appendix 2). We also imputed for missing GAF using multiple imputation (SAS PROC MI and PROC MI ANALYZE) and compared the results obtained using the category of "missing" GAF with the results obtained after imputing missing GAF scores.
Independent Variable: Psychiatry Hospitalization
We used a linked VA-Medicare data set to identify psychiatric hospitalization events. We examined inpatient codes during fiscal years 2002-2008 and considered a hospitalization to be psychiatric when its primary discharge diagnosis was on the list we had used to define MHCs.
Other Independent Variables
Other independent variables included age, gender, race, indications for anticoagulation, date of warfarin inception, comorbidities, alcohol abuse, non-alcohol substance abuse, and the number of non-warfarin medications and hospitalizations. Comorbidities included cancer, chronic kidney disease, chronic liver disease, chronic lung disease, dementia, diabetes, epilepsy, heart failure, hypertension, and stroke. In our Cox regression model, we adjusted for known risk factors for bleeding based on the HAS-BLED bleeding risk assessment model for patients on warfarin for atrial fibrillation. 28 Based on data availability, we created a HAS-BLED-derived factor set, which included age, hypertension, abnormal liver function, chronic kidney disease, labile INR, and alcohol abuse. We were unable to control for two variables that are part of the HAS-BLED score, namely prior bleeding and non-steroidal anti-inflammatory drugs, because of the inability to identify these variables with confidence in our data set.
Dependent Variable: Anticoagulation Control
We used Rosendaal's method 29 to calculate the percent time in the therapeutic range (TTR) for each patient. We assigned an international normalized ratio (INR) value to each day between successively recorded INR values using linear interpolation and computed TTR based on the fraction of time (0-100 %) during which these interpolated values fell between 2 and 3, which is the target INR range for most indications for warfarin therapy. In the multivariate model for major hemorrhage, we defined TTR to be a six-level categorical variable based on the following ranges: 0-30 %, 31-40 %, 41-50 %, 51-60 %, 61-70 %, and 71-100 %.
Dependent Variable: Major hemorrhage
We identified episodes of major hemorrhage based on an algorithm that we adapted from the definition of the International Society of Thrombosis and Haemostasis (ISTH) for use with our automated VA-Medicare data set. 30 Those patients with Medicare Part C were excluded from analyses of hemorrhage because of a high likelihood of incomplete event ascertainment, as Medicare Part C does not generate itemized bills for episodes of care. We aggregated the ICD-9 codes for hemorrhage and determined an event to be a "major hemorrhage" based one of four criteria: bleeding associated with death within 30 days, lifethreatening bleeding into a critical anatomic site, bleeding accompanied by a blood transfusion, or bleeding as the primary reason for hospital admission.
Analyses
We conducted bivariate analyses to compare the clinical and demographic characteristics of patients with and without MHCs and to compare TTR for patients with different MHCs, GAF scores, and psychiatric hospitalization history.
We created four nested linear regression models to determine the association between MHCs and TTR. In model 1, we included only MHCs, and in model 2, we adjusted for gender, age, and race. In model 3, we adjusted additionally for comorbid conditions, and in model 4, we added an additional covariate including date of warfarin inception, primary indication for warfarin, and the number of non-warfarin medications and hospitalizations.
We also created four Cox proportional hazards regression models to determine the effect of different MHCs and other independent variables after adjusting for known predictors of bleeding. We censored patients after the first major hemorrhage event, and TTR was included in the model as a six-level categorical variable. Those patients with Medicare Part C were excluded from analysis because of incomplete event ascetainment 30 . In model 1, we analyzed the effect of any MHC on major hemorrhage, and in model 2, we analyzed the effect of individual MHCs on major hemorrhage. Both models included the entire study population. Models 3 and 4 included only patients with MHCs to determine the additional effect of GAF, hospitalization, and specific MHCs. In model 3, those missing GAF scores in the database were included in the analysis as a separate category. In model 4, those without GAF were included in the model based on GAF values derived from the imputation algorithm using SAS PROC MI and PROC MI ANALYZE.
In addition, we performed a propensity score match between patients with and without MHCs to generate a set of matched "controls" without MHCs whose data looked like the MHC patients in other respects, including demographics, comorbid conditions, and anticoagulation control.
We then computed the hazard ratio of major hemorrhage between patients with MHCs and their propensity-matched controls. We performed all statistical analyses using SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
Among 103,897 experienced warfarin users, 28,216 (27.2 %) had at least one of the MHCs examined in our study. Patients with MHCs were more likely to be female, of non-white race, and have venous thromboembolism as the primary indication for warfarin (Table 1) . Although they were younger, patients with MHCs had more comorbidities and substance abuse issues than those without MHCs, including chronic lung disease (35.9 % vs. 26.7 %, p<0.001), alcohol abuse (17.1 % vs. 6.3 %, p<0.001), and non-alcohol substance abuse (9.8 % vs. 1.8 %, p<0.001). Table 2 shows that those with MHCs had worse anticoagulation control compared to those without MHCs (TTR 57.1 % vs. 63.2 %, p<0.001), and those with a psychiatric hospitalization history experienced even poorer anticoagulation control than MHC patients without such history (50.5 % vs. 57.6 %, p<0.001). The additional TTR reduction attributable to hospitalization ranged from 3.5 % for those with anxiety disorder to 7.1 % for those with bipolar disorder.
Unadjusted Effect of Psychiatric Hospitalization
Unadjusted Effect of GAF
Lower GAF scores were associated with worse anticoagulation control (Table 3) . Compared to those with GAF scores of 51-70, patients with lower GAF scores of 31-50 and 0-30 recorded lower TTR (54.3 % and 49.0 % vs. 57.3 %, p<0.05), while those with GAF scores above 70 recorded higher TTR (60.9 % vs. 57.3 %, p<0.05). Table 4 includes the results of linear regression analysis of the association between specific MHCs and TTR. The results showed that those with bipolar disorder, depression, and other psychotic disorders had statistically significant decreased TTR in all four models. After adjusting for all available covariates, those with bipolar disorder had a 2.63 % decrease in TTR, while those with depression and other psychotic disorders had 2.26 % and 2.92 % decreases, respectively (p<0.001 for all 3 comparisons). Table 5 includes four nested Cox regression models to predict major hemorrhage. Models 1 and 2 showed the effect of any MHC and of specific types of MHC among the entire study population. Compared to those without MHCs, patients with any MHC had an increased hazard for major hemorrhage after adjusting for known bleeding risk factors (i.e., HAS-BLED) (HR 1.19, p<0.001). In particular, patients with anxiety disorders, depression, and other psychotic disorders had slightly increased hazard for hemorrhage, compared to patients without MHCs (HR 1.13, p=0.03; HR 1.16, p<0.001; HR 1.25, p=0.01).
Multivariate Analysis of TTR
Hazard Rates of Major Hemorrhage
Models 3 and 4 included only those with MHCs. After adjusting for known predictors of bleeding, in model 3, higher GAF showed a trend toward decreased hemorrhage, but this trend was not statistically significant. After imputation of missing GAF scores (model 4), the GAF no longer showed any trend. In addition, psychiatric hospitalization was not associated with increased hemorrhage in We repeated our main analysis regarding the hazard for major hemorrhage among this propensity-matched sample. There was no statistically significant difference between the groups, but if anything the patients with MHCs appeared to have a trend toward a reduced hazard for major hemorrhage compared to matched control patients (HR 0.94, 95 % CI: 0.87-1.01).
DISCUSSION
Our study examined outcomes of anticoagulation therapy among patients with and without MHCs, including anticoagulation control and major hemorrhage. In addition, our study is the first to examine putative severity indicators among patients with MHCs and their association with such outcomes. Our findings suggest that patients with MHCs had worse anticoagulation control as indicated by lower TTR, particularly among patients with bipolar disorder, depression, and other psychotic disorders. However, while patients with MHC did have a statistically significant increase in the hazard for major hemorrhage, the magnitude of this effect was small and likely not clinically significant. The propensity matched analysis also supports the contention that patients with and without MHCs did not differ significantly with regard to hemorrhage, especially after controlling for other patient factors. Also, other predictors including GAF and psychiatric hospitalization did not confer an increased bleeding risk among patients with MHCs. In our database, 27 % of patients receiving warfarin from the VA carried a diagnosis for one or more MHCs. Compared to the 1999 Veteran's Large Health Survey 20 (Online Appendix 5), patients with depression, anxiety, and PTSD were not underrepresented in our study compared to the prevalence of these conditions among the overall population of VA patients. This similar prevalence suggests that our study's finding of no clinically significantly increased bleeding risk may be applicable to the general population of VA patients with depression, anxiety, and PTSD. However, patients with schizophrenia and bipolar disorder were under-represented in our database compared to their known prevalence in the VA population. This suggests that the patients with these conditions who were included in our study, because they received warfarin therapy, may have been more highly selected as likely ideal candidates for warfarin therapy.
Our observational study specifically examined the outcomes among patients whose clinicians thought that they were acceptable recipients of warfarin therapy beyond 6 months. We did not include patients needing anticoagulation who were never started on warfarin therapy, treated with warfarin for less than 6 months, and those who might have been judged to have unacceptably high risks for adverse outcomes by their clinicians. One area of additional examination would be to look at patients who were started on warfarin but were not continued on it for a full 6 months to see whether there is a difference in mental health attributes. Other areas of inquiry may include looking at additional barriers to care, such as health literacy and medication adherence, as possible contributors to differences in anticoagulation control.
Limitations
Our study has several limitations. While our database allowed us to study a large population of patients, we could not validate the completeness and accuracy of administrative data. Because our method of categorization differed from other studies 31 , direct comparison of studies might be difficult. While our algorithm 30 for identifying major hemorrhage had face validity, it clearly could not be as precise as a chart review. Moreover, we lacked the data power to identify new thromboembolic events, which could have been contrasted with bleeding rates to better evaluate the overall risk and benefit of warfarin therapy. Finally, our study included only those patients who were already considered to be appropriate for warfarin therapy, who actually received anticoagulation in the VA during our study period, and who remained on it successfully for at least 6 months. We did not specifically look for those who were taken off of warfarin during the study period to determine the impact of MHCs on the rate of warfarin discontinuation. Therefore, the study clearly was not reflective of what would have happened if all patients with MHCs and an indication for warfarin had received it.
CONCLUSIONS
Our study showed, among patients who had received warfarin for 6 or more months, that patients with MHCs did not have a meaningfully increased hazard for major hemorrhage as compared to those without MHCs, and could safely continue on warfarin therapy beyond 6 months. Subgroups of patients with MHCs experienced slightly worse anticoagulation control as indicated by lower TTR, but overall they did not experience clinically significant increases in major hemorrhage. We lacked data to determine whether they had experienced increased stroke or venous thromboembolic events. Those with other psychotic conditions showed a statistically significant increased risk of major hemorrhage, but this small increase might not translate into significance in clinical practice, and the result should be interpreted with the large size of our database in mind.
Our study therefore provides a reassuring message regarding warfarin therapy in patients with MHCs, in that most patients with MHCs do not experience clinically significant increased major hemorrhage, and suggests that most mental health conditions do not, by themselves, represent a contraindication to warfarin therapy. However, our study cannot be used to predict which patients with MHCs a priori will be good candidates for initiation of warfarin therapy as we limited the analysis to those who had already received treatment for 6 or more months. Additional studies should be done to determine the characteristics of patient with MHCs associated with early warfarin discontinuation to help identify additional risk factors for adverse outcomes.
